Replimune Group Target of Unusually Large Options Trading (NASDAQ:REPL)

Replimune Group, Inc. (NASDAQ:REPL) was the target of unusually large options trading activity on Monday. Stock traders acquired 23,181 put options on the stock. This represents an increase of 175% compared to the typical daily volume of 8,439 put options.

Insiders Place Their Bets

In related news, insider Christopher Sarchi sold 12,000 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the transaction, the insider directly owned 180,962 shares in the company, valued at approximately $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Large investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Replimune Group by 17.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock valued at $435,000 after acquiring an additional 6,653 shares in the last quarter. Millennium Management LLC raised its stake in Replimune Group by 2.8% in the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock valued at $11,927,000 after purchasing an additional 33,574 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Replimune Group by 20.9% in the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock valued at $6,729,000 after purchasing an additional 119,145 shares in the last quarter. Rhumbline Advisers lifted its position in Replimune Group by 6.9% during the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock valued at $948,000 after purchasing an additional 6,616 shares during the last quarter. Finally, Sei Investments Co. grew its stake in Replimune Group by 149.5% in the 2nd quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock worth $283,000 after buying an additional 18,263 shares in the last quarter. Institutional investors own 92.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on REPL shares. BMO Capital Markets raised Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective for the company in a report on Tuesday, June 30th. Piper Sandler cut Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price objective on the stock. in a research note on Friday, April 10th. Cantor Fitzgerald downgraded shares of Replimune Group from an “overweight” rating to a “hold” rating in a report on Monday, April 13th. Weiss Ratings lowered shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 2nd. Finally, HC Wainwright reaffirmed a “sell” rating on shares of Replimune Group in a report on Monday, April 13th. Two equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $8.12.

Replimune Group Price Performance

Shares of NASDAQ:REPL opened at $9.87 on Wednesday. The company has a 50 day moving average of $8.31 and a 200 day moving average of $7.38. The stock has a market cap of $828.49 million, a P/E ratio of -2.92 and a beta of 0.86. Replimune Group has a 12 month low of $1.50 and a 12 month high of $13.24. The company has a current ratio of 4.79, a quick ratio of 4.79 and a debt-to-equity ratio of 0.63.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, sell-side analysts forecast that Replimune Group will post -2.29 EPS for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.